Concepts (346)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychomotor Performance | 73 | 2012 | 496 | 7.120 |
Why?
|
| Analgesics, Opioid | 32 | 2014 | 444 | 4.900 |
Why?
|
| Oxycodone | 14 | 2013 | 35 | 4.690 |
Why?
|
| Nitrous Oxide | 28 | 2010 | 107 | 4.170 |
Why?
|
| Affect | 42 | 2011 | 387 | 3.350 |
Why?
|
| Morphine | 19 | 2014 | 130 | 2.600 |
Why?
|
| Narcotics | 12 | 2012 | 70 | 2.390 |
Why?
|
| Anesthetics, Inhalation | 13 | 2018 | 98 | 2.180 |
Why?
|
| Double-Blind Method | 64 | 2018 | 1719 | 2.140 |
Why?
|
| Cross-Over Studies | 45 | 2018 | 389 | 2.100 |
Why?
|
| Substance-Related Disorders | 18 | 2011 | 415 | 1.860 |
Why?
|
| Cognition | 23 | 2011 | 580 | 1.480 |
Why?
|
| Dose-Response Relationship, Drug | 42 | 2019 | 1942 | 1.430 |
Why?
|
| Ethanol | 11 | 2011 | 250 | 1.230 |
Why?
|
| Choice Behavior | 12 | 2008 | 160 | 1.200 |
Why?
|
| Pain | 10 | 2013 | 400 | 1.190 |
Why?
|
| Motivation | 8 | 2013 | 296 | 1.170 |
Why?
|
| Alcohol Drinking | 8 | 2009 | 273 | 1.160 |
Why?
|
| Adult | 104 | 2019 | 26607 | 1.120 |
Why?
|
| Methyl Ethers | 6 | 2008 | 33 | 1.100 |
Why?
|
| Arousal | 13 | 2005 | 170 | 1.030 |
Why?
|
| Opioid-Related Disorders | 9 | 2012 | 189 | 1.000 |
Why?
|
| Smoking | 11 | 2013 | 621 | 0.970 |
Why?
|
| Analgesics | 4 | 2013 | 119 | 0.950 |
Why?
|
| Male | 107 | 2019 | 42411 | 0.900 |
Why?
|
| Hydrocodone | 3 | 2008 | 7 | 0.850 |
Why?
|
| Female | 98 | 2019 | 46202 | 0.820 |
Why?
|
| Carisoprodol | 2 | 2011 | 4 | 0.790 |
Why?
|
| Analgesics, Non-Narcotic | 5 | 2008 | 48 | 0.780 |
Why?
|
| Psychomotor Disorders | 4 | 2008 | 20 | 0.740 |
Why?
|
| Sex Characteristics | 4 | 2010 | 326 | 0.720 |
Why?
|
| Pain Measurement | 10 | 2013 | 329 | 0.720 |
Why?
|
| Drug Interactions | 13 | 2012 | 245 | 0.680 |
Why?
|
| Humans | 126 | 2019 | 89357 | 0.680 |
Why?
|
| Fentanyl | 9 | 1996 | 67 | 0.670 |
Why?
|
| Cold Temperature | 8 | 2004 | 160 | 0.650 |
Why?
|
| Butorphanol | 4 | 2004 | 9 | 0.650 |
Why?
|
| Euphoria | 6 | 2010 | 43 | 0.640 |
Why?
|
| Memory | 7 | 2012 | 220 | 0.580 |
Why?
|
| Behavior | 5 | 1999 | 85 | 0.570 |
Why?
|
| Emotions | 4 | 2011 | 349 | 0.530 |
Why?
|
| Sex Factors | 5 | 2019 | 1066 | 0.510 |
Why?
|
| Muscle Relaxants, Central | 2 | 2011 | 10 | 0.490 |
Why?
|
| Propofol | 6 | 1996 | 92 | 0.480 |
Why?
|
| Nausea | 2 | 2013 | 176 | 0.460 |
Why?
|
| Hemodynamics | 10 | 2008 | 731 | 0.460 |
Why?
|
| Immersion | 4 | 2004 | 21 | 0.450 |
Why?
|
| Isoflurane | 4 | 2018 | 64 | 0.450 |
Why?
|
| Hydromorphone | 3 | 2011 | 11 | 0.450 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 146 | 0.450 |
Why?
|
| Prescription Drug Misuse | 1 | 2013 | 13 | 0.450 |
Why?
|
| Marijuana Smoking | 5 | 1992 | 28 | 0.440 |
Why?
|
| Analysis of Variance | 10 | 2009 | 899 | 0.430 |
Why?
|
| Naltrexone | 1 | 2014 | 136 | 0.420 |
Why?
|
| Injections, Intravenous | 14 | 2001 | 240 | 0.420 |
Why?
|
| Anticonvulsants | 2 | 2011 | 125 | 0.420 |
Why?
|
| GABA Modulators | 1 | 2012 | 8 | 0.410 |
Why?
|
| Alprazolam | 1 | 2012 | 4 | 0.410 |
Why?
|
| Young Adult | 10 | 2014 | 6312 | 0.400 |
Why?
|
| Pupil | 5 | 2014 | 20 | 0.390 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2011 | 28 | 0.390 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2011 | 85 | 0.380 |
Why?
|
| Administration, Inhalation | 10 | 2008 | 190 | 0.370 |
Why?
|
| Surveys and Questionnaires | 14 | 2011 | 2624 | 0.370 |
Why?
|
| Food Deprivation | 4 | 1992 | 24 | 0.370 |
Why?
|
| Analgesia | 3 | 1999 | 58 | 0.360 |
Why?
|
| Receptors, Opioid, mu | 4 | 2014 | 45 | 0.360 |
Why?
|
| Midazolam | 6 | 1996 | 48 | 0.350 |
Why?
|
| Pain Threshold | 4 | 1998 | 61 | 0.350 |
Why?
|
| Blood Pressure | 7 | 2005 | 900 | 0.350 |
Why?
|
| Mental Recall | 5 | 2007 | 158 | 0.330 |
Why?
|
| Acetaminophen | 2 | 2008 | 56 | 0.330 |
Why?
|
| Reaction Time | 7 | 2012 | 310 | 0.330 |
Why?
|
| Codeine | 3 | 2005 | 12 | 0.320 |
Why?
|
| Dextroamphetamine | 4 | 1992 | 108 | 0.320 |
Why?
|
| Anxiety | 1 | 2011 | 308 | 0.320 |
Why?
|
| Alcoholic Intoxication | 1 | 2008 | 32 | 0.310 |
Why?
|
| Reference Values | 8 | 2009 | 661 | 0.310 |
Why?
|
| Drug Combinations | 4 | 2011 | 203 | 0.300 |
Why?
|
| Caffeine | 3 | 2018 | 83 | 0.290 |
Why?
|
| Naloxone | 2 | 1999 | 67 | 0.290 |
Why?
|
| Anesthetics, Intravenous | 2 | 1997 | 41 | 0.280 |
Why?
|
| Central Nervous System Depressants | 2 | 1997 | 45 | 0.280 |
Why?
|
| Meperidine | 2 | 1999 | 13 | 0.280 |
Why?
|
| Narcotic Antagonists | 3 | 2014 | 160 | 0.270 |
Why?
|
| Fasting | 3 | 1992 | 163 | 0.270 |
Why?
|
| Automobile Driver Examination | 1 | 2006 | 1 | 0.270 |
Why?
|
| Drug Prescriptions | 2 | 2008 | 144 | 0.270 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 87 | 0.260 |
Why?
|
| Automobile Driving | 1 | 2006 | 31 | 0.260 |
Why?
|
| Impulsive Behavior | 1 | 2009 | 287 | 0.260 |
Why?
|
| Histamine H2 Antagonists | 1 | 2005 | 15 | 0.260 |
Why?
|
| Motor Skills | 1 | 2006 | 79 | 0.250 |
Why?
|
| Tramadol | 1 | 2005 | 14 | 0.250 |
Why?
|
| Carbon Monoxide | 8 | 1992 | 93 | 0.250 |
Why?
|
| Proton Pump Inhibitors | 1 | 2005 | 34 | 0.250 |
Why?
|
| Administration, Oral | 6 | 2011 | 682 | 0.250 |
Why?
|
| Cognition Disorders | 2 | 2005 | 235 | 0.240 |
Why?
|
| Substance Abuse Detection | 3 | 2013 | 12 | 0.240 |
Why?
|
| Valerian | 1 | 2004 | 3 | 0.240 |
Why?
|
| Dextropropoxyphene | 1 | 2004 | 2 | 0.240 |
Why?
|
| Plant Preparations | 1 | 2004 | 21 | 0.230 |
Why?
|
| Lorazepam | 4 | 2005 | 14 | 0.230 |
Why?
|
| Alcoholism | 2 | 1999 | 178 | 0.230 |
Why?
|
| Anesthetics | 3 | 1999 | 53 | 0.230 |
Why?
|
| Drug and Narcotic Control | 1 | 2003 | 7 | 0.220 |
Why?
|
| Respiration | 7 | 1999 | 267 | 0.220 |
Why?
|
| Gastroesophageal Reflux | 1 | 2005 | 122 | 0.220 |
Why?
|
| Marijuana Abuse | 2 | 1994 | 26 | 0.220 |
Why?
|
| Heart Rate | 6 | 2014 | 495 | 0.220 |
Why?
|
| Anesthesia Recovery Period | 3 | 2018 | 56 | 0.220 |
Why?
|
| Tropanes | 1 | 2002 | 2 | 0.210 |
Why?
|
| Nicotine | 5 | 1993 | 199 | 0.210 |
Why?
|
| Preanesthetic Medication | 1 | 2002 | 6 | 0.200 |
Why?
|
| Dental Anxiety | 1 | 2002 | 2 | 0.200 |
Why?
|
| Anesthesia, Dental | 1 | 2002 | 4 | 0.200 |
Why?
|
| Risk Factors | 9 | 2013 | 5499 | 0.200 |
Why?
|
| Time Factors | 11 | 2018 | 5338 | 0.190 |
Why?
|
| Placebos | 4 | 2011 | 214 | 0.190 |
Why?
|
| Anesthesiology | 3 | 1999 | 162 | 0.190 |
Why?
|
| Thiopental | 2 | 1997 | 15 | 0.180 |
Why?
|
| Infusions, Intravenous | 3 | 2014 | 435 | 0.170 |
Why?
|
| Prospective Studies | 9 | 2013 | 4289 | 0.170 |
Why?
|
| Anesthetics, Combined | 1 | 1999 | 4 | 0.170 |
Why?
|
| Azepines | 1 | 2019 | 25 | 0.170 |
Why?
|
| Alfentanil | 1 | 1999 | 2 | 0.170 |
Why?
|
| Research Design | 2 | 2013 | 599 | 0.170 |
Why?
|
| Drug Tolerance | 3 | 1996 | 64 | 0.160 |
Why?
|
| Pentazocine | 1 | 1998 | 2 | 0.160 |
Why?
|
| Citrates | 1 | 2018 | 28 | 0.160 |
Why?
|
| Attention | 5 | 2007 | 395 | 0.160 |
Why?
|
| Hypnotics and Sedatives | 2 | 1996 | 131 | 0.150 |
Why?
|
| Psychotropic Drugs | 1 | 1999 | 78 | 0.150 |
Why?
|
| Anesthesia | 2 | 1999 | 170 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2013 | 838 | 0.150 |
Why?
|
| Ethers | 1 | 1997 | 14 | 0.150 |
Why?
|
| Verapamil | 2 | 1997 | 34 | 0.150 |
Why?
|
| Adjuvants, Anesthesia | 1 | 1997 | 5 | 0.150 |
Why?
|
| Neuropsychological Tests | 4 | 2012 | 505 | 0.150 |
Why?
|
| Piperidines | 1 | 1999 | 166 | 0.150 |
Why?
|
| Individuality | 3 | 2008 | 110 | 0.150 |
Why?
|
| Risk | 2 | 2013 | 657 | 0.150 |
Why?
|
| Nalbuphine | 1 | 1997 | 3 | 0.150 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 121 | 0.140 |
Why?
|
| Accidents, Occupational | 1 | 1996 | 8 | 0.140 |
Why?
|
| Buprenorphine | 1 | 1997 | 41 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2019 | 318 | 0.140 |
Why?
|
| Anti-Anxiety Agents | 1 | 1996 | 23 | 0.140 |
Why?
|
| Methadone | 1 | 1996 | 46 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2019 | 374 | 0.140 |
Why?
|
| Self Administration | 3 | 2008 | 72 | 0.130 |
Why?
|
| Dronabinol | 3 | 1992 | 56 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2018 | 219 | 0.130 |
Why?
|
| Flumazenil | 1 | 1995 | 8 | 0.130 |
Why?
|
| Accidents, Traffic | 1 | 1996 | 98 | 0.130 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2015 | 4 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1995 | 47 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1047 | 0.130 |
Why?
|
| Miosis | 3 | 2004 | 10 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2019 | 8241 | 0.120 |
Why?
|
| Anilides | 1 | 2015 | 48 | 0.120 |
Why?
|
| Breath Tests | 4 | 2001 | 57 | 0.120 |
Why?
|
| Respiratory Mechanics | 2 | 2008 | 102 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1996 | 242 | 0.120 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2014 | 80 | 0.120 |
Why?
|
| Nifedipine | 1 | 1993 | 25 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 1995 | 232 | 0.110 |
Why?
|
| Population | 1 | 2013 | 35 | 0.110 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 155 | 0.110 |
Why?
|
| Endpoint Determination | 1 | 2013 | 61 | 0.110 |
Why?
|
| Anesthesia, Intravenous | 1 | 1993 | 35 | 0.110 |
Why?
|
| Hair | 1 | 1993 | 56 | 0.110 |
Why?
|
| Social Environment | 2 | 1992 | 187 | 0.110 |
Why?
|
| Ondansetron | 1 | 1993 | 21 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2019 | 9057 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 175 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1993 | 25 | 0.110 |
Why?
|
| Pyridines | 1 | 2015 | 315 | 0.110 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1993 | 59 | 0.100 |
Why?
|
| Cycloparaffins | 1 | 1992 | 5 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2013 | 221 | 0.100 |
Why?
|
| Toxicity Tests, Acute | 1 | 2011 | 2 | 0.100 |
Why?
|
| Pregabalin | 1 | 2011 | 6 | 0.100 |
Why?
|
| Thinking | 1 | 2012 | 35 | 0.100 |
Why?
|
| Respiratory Rate | 1 | 2011 | 20 | 0.100 |
Why?
|
| Neurology | 1 | 2012 | 74 | 0.100 |
Why?
|
| Social Isolation | 1 | 1992 | 67 | 0.100 |
Why?
|
| Drug Discovery | 1 | 2012 | 107 | 0.100 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 2 | 1990 | 5 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 588 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 895 | 0.090 |
Why?
|
| Plants, Toxic | 2 | 1987 | 25 | 0.090 |
Why?
|
| Leukemia, Myeloid | 1 | 2011 | 249 | 0.090 |
Why?
|
| Amphetamines | 1 | 1990 | 18 | 0.090 |
Why?
|
| Psychopharmacology | 1 | 2009 | 26 | 0.090 |
Why?
|
| Procaine | 1 | 1989 | 11 | 0.080 |
Why?
|
| Pentobarbital | 1 | 1989 | 20 | 0.080 |
Why?
|
| Social Values | 1 | 2009 | 44 | 0.080 |
Why?
|
| Cannabis | 1 | 1990 | 35 | 0.080 |
Why?
|
| Lidocaine | 1 | 1989 | 65 | 0.080 |
Why?
|
| Psychological Tests | 1 | 2009 | 91 | 0.080 |
Why?
|
| Conditioning, Operant | 4 | 2008 | 71 | 0.080 |
Why?
|
| Cotinine | 3 | 1997 | 12 | 0.080 |
Why?
|
| Methamphetamine | 1 | 1990 | 85 | 0.080 |
Why?
|
| Cocaine | 1 | 1989 | 76 | 0.080 |
Why?
|
| Drug Evaluation | 1 | 2008 | 138 | 0.080 |
Why?
|
| Placebo Effect | 1 | 2008 | 30 | 0.080 |
Why?
|
| Norepinephrine | 3 | 2005 | 172 | 0.080 |
Why?
|
| Drug Design | 1 | 2008 | 127 | 0.070 |
Why?
|
| Reward | 1 | 2009 | 188 | 0.070 |
Why?
|
| Health Surveys | 1 | 2008 | 240 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1150 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 92 | 0.070 |
Why?
|
| Smoke | 1 | 1986 | 27 | 0.070 |
Why?
|
| Neoplasms | 2 | 2019 | 3041 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1862 | 0.070 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2006 | 22 | 0.070 |
Why?
|
| Middle Aged | 8 | 2019 | 25974 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 203 | 0.070 |
Why?
|
| Ambulatory Surgical Procedures | 3 | 1995 | 75 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 784 | 0.060 |
Why?
|
| Water | 2 | 1997 | 283 | 0.060 |
Why?
|
| Self Concept | 1 | 2005 | 133 | 0.060 |
Why?
|
| Heroin Dependence | 2 | 2011 | 14 | 0.060 |
Why?
|
| Forearm | 1 | 2004 | 31 | 0.060 |
Why?
|
| Drug Synergism | 2 | 1998 | 306 | 0.060 |
Why?
|
| Prevalence | 1 | 2008 | 1243 | 0.060 |
Why?
|
| Serotonin | 1 | 2005 | 221 | 0.060 |
Why?
|
| Oxygen | 3 | 1999 | 743 | 0.060 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 2004 | 24 | 0.060 |
Why?
|
| Reinforcement Schedule | 3 | 2008 | 17 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2004 | 245 | 0.050 |
Why?
|
| Volunteers | 1 | 2001 | 21 | 0.050 |
Why?
|
| Adolescent | 5 | 1993 | 9263 | 0.050 |
Why?
|
| Random Allocation | 2 | 1993 | 327 | 0.050 |
Why?
|
| Amitriptyline | 1 | 2001 | 11 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2002 | 234 | 0.050 |
Why?
|
| Gait | 1 | 2001 | 81 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2001 | 111 | 0.040 |
Why?
|
| Sleep | 2 | 1996 | 452 | 0.040 |
Why?
|
| Consumer Behavior | 1 | 1999 | 31 | 0.040 |
Why?
|
| Sensation | 1 | 1999 | 47 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2019 | 58 | 0.040 |
Why?
|
| Indazoles | 1 | 2019 | 67 | 0.040 |
Why?
|
| Incidence | 1 | 2003 | 1595 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 2303 | 0.040 |
Why?
|
| Attitude | 1 | 1999 | 130 | 0.040 |
Why?
|
| Drug Utilization | 1 | 1999 | 66 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 272 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2001 | 461 | 0.040 |
Why?
|
| Aged | 4 | 2019 | 19165 | 0.040 |
Why?
|
| Nimodipine | 1 | 1997 | 11 | 0.040 |
Why?
|
| Diltiazem | 1 | 1997 | 7 | 0.040 |
Why?
|
| Mental Competency | 1 | 1997 | 49 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 1714 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 576 | 0.040 |
Why?
|
| Infusion Pumps | 1 | 1996 | 25 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 860 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 1999 | 378 | 0.030 |
Why?
|
| Recurrence | 1 | 1999 | 1144 | 0.030 |
Why?
|
| Motor Activity | 1 | 1999 | 327 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 218 | 0.030 |
Why?
|
| Columbidae | 4 | 1990 | 4 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1214 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 1996 | 37 | 0.030 |
Why?
|
| Long-Term Care | 1 | 1996 | 61 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 1996 | 137 | 0.030 |
Why?
|
| United States | 2 | 2012 | 6989 | 0.030 |
Why?
|
| Coffee | 1 | 1995 | 10 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1996 | 150 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1534 | 0.030 |
Why?
|
| Sleep Deprivation | 1 | 1996 | 138 | 0.030 |
Why?
|
| Informed Consent | 1 | 1997 | 275 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 3666 | 0.030 |
Why?
|
| Pressure | 1 | 1995 | 165 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1998 | 950 | 0.030 |
Why?
|
| Personality Inventory | 1 | 1994 | 109 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 162 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1870 | 0.030 |
Why?
|
| Temperature | 1 | 1995 | 404 | 0.030 |
Why?
|
| Reflex, Pupillary | 1 | 1994 | 8 | 0.030 |
Why?
|
| Sufentanil | 1 | 1993 | 3 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 2018 | 0.030 |
Why?
|
| Smell | 1 | 1994 | 111 | 0.030 |
Why?
|
| Generalization, Stimulus | 2 | 1990 | 3 | 0.030 |
Why?
|
| Models, Biological | 1 | 1999 | 1765 | 0.030 |
Why?
|
| Pulse | 1 | 1992 | 17 | 0.030 |
Why?
|
| Internationality | 1 | 2012 | 69 | 0.030 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1992 | 16 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 2872 | 0.030 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 1990 | 70 | 0.030 |
Why?
|
| Hunger | 1 | 1992 | 23 | 0.030 |
Why?
|
| Verbal Behavior | 1 | 1992 | 32 | 0.020 |
Why?
|
| Animals | 6 | 1999 | 27371 | 0.020 |
Why?
|
| Personality Assessment | 1 | 1992 | 97 | 0.020 |
Why?
|
| Memory, Short-Term | 3 | 2005 | 227 | 0.020 |
Why?
|
| Energy Intake | 1 | 1992 | 97 | 0.020 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1992 | 89 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2011 | 78 | 0.020 |
Why?
|
| Ketone Bodies | 1 | 1991 | 16 | 0.020 |
Why?
|
| Dopamine | 2 | 1983 | 276 | 0.020 |
Why?
|
| Hormones | 1 | 2011 | 139 | 0.020 |
Why?
|
| Cytarabine | 1 | 2011 | 219 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1992 | 202 | 0.020 |
Why?
|
| Fenfluramine | 1 | 1990 | 20 | 0.020 |
Why?
|
| Drinking Behavior | 1 | 1990 | 13 | 0.020 |
Why?
|
| Glycosuria | 1 | 1989 | 4 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 312 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1990 | 88 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 1993 | 253 | 0.020 |
Why?
|
| Amphetamine | 1 | 1990 | 101 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 36 | 0.020 |
Why?
|
| Filtration | 1 | 1986 | 25 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2010 | 856 | 0.020 |
Why?
|
| Volatilization | 1 | 2005 | 6 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1989 | 836 | 0.020 |
Why?
|
| Time Perception | 1 | 2005 | 24 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2005 | 29 | 0.020 |
Why?
|
| Problem Solving | 1 | 2005 | 54 | 0.020 |
Why?
|
| Discrimination Learning | 1 | 2005 | 63 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 2005 | 69 | 0.020 |
Why?
|
| Rats | 1 | 1990 | 4041 | 0.010 |
Why?
|
| Stereotyped Behavior | 1 | 1983 | 12 | 0.010 |
Why?
|
| Telencephalon | 1 | 1982 | 31 | 0.010 |
Why?
|
| Desipramine | 1 | 2001 | 9 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2285 | 0.010 |
Why?
|
| Paroxetine | 1 | 2001 | 26 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 244 | 0.010 |
Why?
|
| Lung | 1 | 1987 | 1263 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 2415 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1983 | 322 | 0.010 |
Why?
|
| Droperidol | 1 | 1995 | 3 | 0.010 |
Why?
|
| Ketamine | 1 | 1995 | 25 | 0.010 |
Why?
|
| Reference Standards | 1 | 1995 | 144 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1991 | 302 | 0.010 |
Why?
|
| Learning | 1 | 1993 | 285 | 0.010 |
Why?
|
| Apomorphine | 1 | 1983 | 10 | 0.000 |
Why?
|
| Haloperidol | 1 | 1983 | 29 | 0.000 |
Why?
|
| Pons | 1 | 1982 | 25 | 0.000 |
Why?
|
| Substantia Nigra | 1 | 1982 | 28 | 0.000 |
Why?
|
| Brain Chemistry | 1 | 1983 | 122 | 0.000 |
Why?
|
| Olfactory Bulb | 1 | 1982 | 40 | 0.000 |
Why?
|
| Basal Ganglia | 1 | 1982 | 46 | 0.000 |
Why?
|
| Corpus Striatum | 1 | 1982 | 88 | 0.000 |
Why?
|
| Eating | 1 | 1983 | 166 | 0.000 |
Why?
|
| Neural Pathways | 1 | 1982 | 319 | 0.000 |
Why?
|